US ranitidine litigation unlikely to impact Indian pharma: Analysts

Sun Pharmaceuticals, Dr Reddy's Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 mn with cancer patient Joseph Bayer

The US litigation around antacid drug ranitidine is unlikely to have any material impact on Indian pharma companies at this stage, feel analysts.

According to media reports, Sun Pharmaceuticals, Dr Reddy’s Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 million with cancer patient Joseph Bayer. This is the first settlement in the three-year old ranitidine litigation.

In September 2019, several companies including British drugmaker GlaxoSmithKline Pharma (GSK) and Hyderabad-based Dr Reddy's Laboratories (DRL) had withdrawn their ranitidine products from the market following the US Food and Drug Administration (USFDA) raising concerns around the presence of a